GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (FRA:LTI0) » Definitions » Research & Development

Aptose Biosciences (FRA:LTI0) Research & Development : €13.83 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aptose Biosciences Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Aptose Biosciences's Research & Development for the three months ended in Dec. 2024 was €-0.44 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €13.83 Mil.

Aptose Biosciences Research & Development Historical Data

The historical data trend for Aptose Biosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Research & Development Chart

Aptose Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.08 40.70 26.52 33.71 14.42

Aptose Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.36 5.93 4.10 4.24 -0.44

Aptose Biosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptose Biosciences  (FRA:LTI0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Aptose Biosciences Research & Development Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptose Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (FRA:LTI0) » Definitions » Research & Development
Comparable Companies
TSXV:IBO TSXV:IOT TSXV:QPT XCNQ:LOBE TSXV:XRTX XCNQ:ASEP XCNQ:BLAB XCNQ:GLOW TSXV:RKV TSXV:MRVL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
APTOF:USA 0UI8:UK APS:Canada
Address
66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, ON, CAN, M5K 1E6
Website
https://www.aptose.com
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Aptose Biosciences Headlines

No Headlines